These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30011385)

  • 1. Event simulation and external validation applied in published health economic models for obesity: a systematic review.
    Schwander B; Nuijten M; Hiligsmann M; Evers SMAA
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):529-541. PubMed ID: 30011385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and overview of health economic evaluation models in obesity prevention and therapy.
    Schwander B; Hiligsmann M; Nuijten M; Evers S
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):561-570. PubMed ID: 27570095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study.
    Webber L; Divajeva D; Marsh T; McPherson K; Brown M; Galea G; Breda J
    BMJ Open; 2014 Jul; 4(7):e004787. PubMed ID: 25063459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of obesity-related chronic diseases in Mainland China.
    Zhao W; Zhai Y; Hu J; Wang J; Yang Z; Kong L; Chen C
    Obes Rev; 2008 Mar; 9 Suppl 1():62-7. PubMed ID: 18307701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity.
    Arrospide A; Ibarrondo O; Castilla I; Larrañaga I; Mar J
    Med Decis Making; 2022 Feb; 42(2):241-254. PubMed ID: 34632840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).
    Willis M; Asseburg C; He J
    J Med Econ; 2013 Aug; 16(8):1007-21. PubMed ID: 23718682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime health and economic consequences of obesity.
    Thompson D; Edelsberg J; Colditz GA; Bird AP; Oster G
    Arch Intern Med; 1999 Oct; 159(18):2177-83. PubMed ID: 10527295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data.
    Ahmad Kiadaliri A; Gerdtham UG; Nilsson P; Eliasson B; Gudbjörnsdottir S; Carlsson KS
    PLoS One; 2013; 8(5):e62650. PubMed ID: 23671618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review.
    Ogurtsova K; Heise TL; Linnenkamp U; Dintsios CM; Lhachimi SK; Icks A
    Syst Rev; 2017 Dec; 6(1):267. PubMed ID: 29284543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity.
    Schwander B; Kaier K; Hiligsmann M; Evers S; Nuijten M
    Pharmacoeconomics; 2022 Sep; 40(9):901-915. PubMed ID: 35771486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current estimates of the economic cost of obesity in the United States.
    Wolf AM; Colditz GA
    Obes Res; 1998 Mar; 6(2):97-106. PubMed ID: 9545015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe.
    Hermansson J; Kahan T
    Pharmacoeconomics; 2018 Feb; 36(2):205-213. PubMed ID: 29079929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.
    Mueller E; Maxion-Bergemann S; Gultyaev D; Walzer S; Freemantle N; Mathieu C; Bolinder B; Gerber R; Kvasz M; Bergemann R
    Diabetes Technol Ther; 2006 Apr; 8(2):219-36. PubMed ID: 16734551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
    Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
    Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus.
    Henriksson M; Jindal R; Sternhufvud C; Bergenheim K; Sörstadius E; Willis M
    Pharmacoeconomics; 2016 Jun; 34(6):569-85. PubMed ID: 26792792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.